.png){kind=icon}
.png){kind=icon}
Return
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation
.png){kind=icon}
OA
AI
J
V
C
M
DOI：10.1016/j.pupt.2025.102364.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Orally administered EP395 reduces local neutrophil counts and cytokines in murine acute respiratory inflammation models. • Increased concentrations of the epithelial collectin, SP-D in LPS-stimulated lung washings were also reduced by EP395. • EP395, like azithromycin, demonstrates both acute stimulatory and inhibitory effects on neutrophil function in vitro. • EP395 represents a novel, non-antibacterial anti-inflammatory macrolide for COPD therapy.
Keywords:
COPD
Inflammation
Epithelium
Macrolides
Immunomodulation
Azithromycin
EP395
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
P
IF:
2.8
Papers:
2.1K
Citations:
2.6K
Organization
Cited Papers